Saturday, 08 August 2020


Abexome collaborates with Bioneeds

28 March 2013 | News | By BioSpectrum Bureau

Abexome Biosciences and Bioneeds join hands to provide pre-clinical and core biology services

Abexome Biosciences and Bioneeds join hands to provide pre-clinical and core biology services

Bangalore: Abexome Biosciences, an analytical solution provider to the biopharmaceutical industry and Bioneeds, a leading OECD GLP certified pre-clinical service provider in India, will collaborate in providing pre-clinical and core biology services to pharmaceutical and biopharmaceutical companies in India using their complementary capabilities.

Under this agreement, Abexome and Bioneeds will provide end-to-end solutions including custom antibody and ELISA method development, pharmacokinetic studies, regulatory toxicity studies and in vivo and in vitro efficacy assays for drug screening.

Commenting on the collaboration, Dr Vinay Babu, MD, Bioneeds, said that, "In the past few years Bioneeds has emerged as a leading provider of pre-clinical services whereas Abexome has established its name in the area of ELISA assay method development and cell-based assay development."

Dr Babu added, "This collaboration will enable both organization to access each other's complementary capabilities and offer a wider spectrum of services to pharma and biotech companies particularly biopharmaceuticals."

Dr Sujan K Dhar, CEO, Abexome, said that, "The capabilities of Abexome and Bioneeds are very complementary and we are the ideal partners for each other to create a synergy in form of this collaboration. We are glad to partner with Bioneeds and we believe this partnership can bring more delight to the customers thereby increasing the business value for both organizations."


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls